Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | NOD1 | Q9Y239 | 4/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.31 |
| ▸ | CTSG | P08311 | 1/20 | 0.31 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.31 |
| ▸ | CMA1 | P23946 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30948631 | 0.91 | NOD1 (0.44) | KMT2APOLBFAAHNOD1 | |
| SCHEMBL26940801 | 0.90 | KMT2A (0.35) | KMT2APOLBFAAHL3MBTL1ALDH1A1 | |
| SCHEMBL30682337 | 0.88 | L3MBTL1 (0.35) | KMT2APOLBFAAHL3MBTL1ALDH1A1 | |
| SCHEMBL26940811 | 0.88 | KMT2A (0.34) | KMT2APOLBFAAHL3MBTL1PSMB5 | |
| SCHEMBL26940616 | 0.88 | L3MBTL1 (0.38) | KMT2APOLBFAAHL3MBTL1 | |
| SCHEMBL30682213 | 0.88 | L3MBTL1 (0.38) | KMT2APOLBFAAHL3MBTL1 | |
| SCHEMBL30682192 | 0.86 | L3MBTL1 (0.35) | KMT2APOLBFAAHL3MBTL1 | |
| SCHEMBL26940827 | 0.86 | L3MBTL1 (0.33) | KMT2APOLBFAAHL3MBTL1HDAC2 | |
| SCHEMBL26940613 | 0.86 | L3MBTL1 (0.33) | KMT2APOLBFAAHL3MBTL1ALDH1A1 | |
| SCHEMBL26940805 | 0.86 | L3MBTL1 (0.33) | KMT2APOLBFAAHL3MBTL1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246902-A1 | PRODRUGS OF 6-DIAZO-5-OXO-L-NORLEUCINE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246902-A1 | PRODRUGS OF 6-DIAZO-5-OXO-L-NORLEUCINE | GLUL, GLS, GLS2 | KMT2A 1705/4885POLB 1467/4885FAAH 1065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.